Related Experiment Videos
Mitomycin-C induced hemolytic uremic syndrome: a case report.
Rajaram K Gundappa1, Kamal Sud, Harbir S Kohli
1Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Renal Failure
|August 9, 2002
Summary
Mitomycin-C, a chemotherapy drug, can cause hemolytic uremic syndrome, a serious side effect. This case highlights the risk in patients with colonic adenocarcinoma, even with a single dose.
Area of Science:
- Oncology
- Nephrology
- Pharmacology
Background:
- Mitomycin-C is a widely used chemotherapeutic agent for various malignancies.
- Mitomycin-C is known to cause dose-dependent adverse effects.
- Hemolytic uremic syndrome (HUS) is a recognized severe adverse event associated with Mitomycin-C therapy.
Observation:
- A patient diagnosed with colonic adenocarcinoma received Mitomycin-C.
- The patient was administered a cumulative dose of 85 mg/m2 of Mitomycin-C.
- Following treatment, the patient developed hemolytic uremic syndrome.
Findings:
- The development of HUS in this patient was directly linked to Mitomycin-C administration.
- The patient's HUS was not treated.
- The patient succumbed to a secondary malignancy five months post-HUS diagnosis.
Implications:
- This case underscores the critical need for vigilant monitoring of patients receiving Mitomycin-C for potential HUS development.
- Early recognition and management of Mitomycin-C-induced HUS are crucial for patient outcomes.
- Understanding the differential diagnosis and treatment strategies for HUS is essential in oncology practice.